Trial Profile
Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic NSCLC
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 17 May 2019 Status changed to withdrawn prior to enrolment.
- 11 Aug 2017 Planned End Date changed from 1 Oct 2022 to 1 Jul 2022.
- 11 Aug 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Jul 2020.